42 related articles for article (PubMed ID: 22616991)
1. Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation.
Tatavosian R; Donovan MG; Galbraith MD; Duc HN; Szwarc MM; Joshi MU; Frieman A; Bilousova G; Cao Y; Smith KP; Song K; Rachubinski AL; Andrysik Z; Espinosa JM
Cell Death Differ; 2023 Apr; 30(4):952-965. PubMed ID: 36681780
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.
Lee YK; Heo HH; Kim N; Park UH; Youn H; Moon EY; Kim EJ; Um SJ
BMB Rep; 2024 Jun; ():. PubMed ID: 38835116
[TBL] [Abstract][Full Text] [Related]
3. Gene regulation by the tumor suppressor p53 - The omics era.
Fischer M
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(4):189111. PubMed ID: 38740351
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the prostaglandin D2 signal pathway in retinoid-inducible gene 1 (RIG1)-mediated suppression of cell invasion in testis cancer cells.
Wu CC; Shyu RY; Wang CH; Tsai TC; Wang LK; Chen ML; Jiang SY; Tsai FM
Biochim Biophys Acta; 2012 Dec; 1823(12):2227-36. PubMed ID: 22960220
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.
DiSepio D; Ghosn C; Eckert RL; Deucher A; Robinson N; Duvic M; Chandraratna RA; Nagpal S
Proc Natl Acad Sci U S A; 1998 Dec; 95(25):14811-5. PubMed ID: 9843971
[TBL] [Abstract][Full Text] [Related]
6. Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction.
Zhao JY; Yuan XK; Luo RZ; Wang LX; Gu W; Yamane D; Feng H
Front Immunol; 2023; 14():1107239. PubMed ID: 37063830
[TBL] [Abstract][Full Text] [Related]
7. Basal Level p53 Suppresses Antiviral Immunity against Foot-and-Mouth Disease Virus.
Zhang T; Chen H; Liu X; Qi L; Gao X; Wang K; Yao K; Zhang J; Sun Y; Zhang Y; Wu R
Viruses; 2019 Aug; 11(8):. PubMed ID: 31394868
[TBL] [Abstract][Full Text] [Related]
8. Activity-Based Protein Profiling Identifies α-Ketoamides as Inhibitors for Phospholipase A2 Group XVI.
Zhou J; Mock ED; Martella A; Kantae V; Di X; Burggraaff L; Baggelaar MP; Al-Ayed K; Bakker A; Florea BI; Grimm SH; den Dulk H; Li CT; Mulder L; Overkleeft HS; Hankemeier T; van Westen GJP; van der Stelt M
ACS Chem Biol; 2019 Feb; 14(2):164-169. PubMed ID: 30620559
[TBL] [Abstract][Full Text] [Related]
9. The footprint of the ageing stroma in older patients with breast cancer.
Brouwers B; Fumagalli D; Brohee S; Hatse S; Govaere O; Floris G; Van den Eynde K; Bareche Y; Schöffski P; Smeets A; Neven P; Lambrechts D; Sotiriou C; Wildiers H
Breast Cancer Res; 2017 Jul; 19(1):78. PubMed ID: 28673354
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor p53 protects mice against Listeria monocytogenes infection.
Wang S; Liu P; Wei J; Zhu Z; Shi Z; Shao D; Ma Z
Sci Rep; 2016 Sep; 6():33815. PubMed ID: 27644341
[TBL] [Abstract][Full Text] [Related]
11. RARRES3 regulates signal transduction through post-translational protein modifications.
Hsu TH; Chang TC
Mol Cell Oncol; 2015; 2(4):e999512. PubMed ID: 27308522
[TBL] [Abstract][Full Text] [Related]
12. The HRASLS (PLA/AT) subfamily of enzymes.
Mardian EB; Bradley RM; Duncan RE
J Biomed Sci; 2015 Oct; 22():99. PubMed ID: 26503625
[TBL] [Abstract][Full Text] [Related]
13. RARRES3 suppressed metastasis through suppression of MTDH to regulate epithelial-mesenchymal transition in colorectal cancer.
Wang Z; Wang L; Hu J; Fan R; Zhou J; Wang L; Zhong J
Am J Cancer Res; 2015; 5(6):1988-99. PubMed ID: 26269758
[TBL] [Abstract][Full Text] [Related]
14. The transcription factor p53: not a repressor, solely an activator.
Fischer M; Steiner L; Engeland K
Cell Cycle; 2014; 13(19):3037-58. PubMed ID: 25486564
[TBL] [Abstract][Full Text] [Related]
15. Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells.
Hsu TH; Jiang SY; Chang WL; Eckert RL; Scharadin TM; Chang TC
Cell Death Differ; 2015 May; 22(5):801-14. PubMed ID: 25361079
[TBL] [Abstract][Full Text] [Related]
16. An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation.
Wolf J; Müller-Decker K; Flechtenmacher C; Zhang F; Shahmoradgoli M; Mills GB; Hoheisel JD; Boettcher M
Oncogene; 2014 Aug; 33(33):4273-8. PubMed ID: 24292671
[TBL] [Abstract][Full Text] [Related]
17. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
Wrangle J; Wang W; Koch A; Easwaran H; Mohammad HP; Vendetti F; Vancriekinge W; Demeyer T; Du Z; Parsana P; Rodgers K; Yen RW; Zahnow CA; Taube JM; Brahmer JR; Tykodi SS; Easton K; Carvajal RD; Jones PA; Laird PW; Weisenberger DJ; Tsai S; Juergens RA; Topalian SL; Rudin CM; Brock MV; Pardoll D; Baylin SB
Oncotarget; 2013 Nov; 4(11):2067-79. PubMed ID: 24162015
[TBL] [Abstract][Full Text] [Related]
18. Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines.
Hsu TH; Chu CC; Jiang SY; Hung MW; Ni WC; Lin HE; Chang TC
FEBS Lett; 2012 May; 586(9):1287-93. PubMed ID: 22616991
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of the retinoic acid response elements in the human RIG1 gene promoter.
Jiang SY; Wu MS; Chen LM; Hung MW; Lin HE; Chang GG; Chang TC
Biochem Biophys Res Commun; 2005 Jun; 331(2):630-9. PubMed ID: 15850806
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
